42
Participants
Start Date
February 21, 2022
Primary Completion Date
October 4, 2022
Study Completion Date
October 4, 2022
LMN-101
VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
Placebo
Identical appearing placebo
Pharmaron, Baltimore
Lead Sponsor
Collaborators (2)
Naval Medical Research Center
FED
Pharmaron
INDUSTRY
University of Maryland
OTHER
Lumen Bioscience, Inc.
INDUSTRY